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Abstract  
Vitiligo is an important skin disease of childhood. The authors briefly discuss the etiopathobiology, clinics and 
comorbidities of the disease. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Vitiligo is an acquired, chronic, pigmentary 
disorder characterized by the progressive loss of 
cutaneous melanocytes and abnormality in their 
normal function, resulting in hypopigmented skin 
areas which progressively become amelanotic [1]. 
Different studies underline how half of 
vitiligo patients develop the disease before the age 
of 20 years old and how about 25% of them develop 
the disease before the age of 8 [2]. 
In pediatric age, vitiligo may represent a deep 
psychological trauma for both patients and their 
parents, and leads to a poor quality of life [3]. Even if 
the treatment of the disease is mail goal for 
dermatologists, a better understanding of vitiligo 
may be helpful for a better management of the 
patient. 
 
 
Etiology 
 
As well-known, vitiligo is inherited in a non-
Mendelian, multifactorial and polygenic pattern. 
A part for gene encoding molecules relevant 
for the normal melanogenesis (e.g. TYR which 
encode for Tyrosinase), recent studies show a strong 
association of vitiligo with particular HLA haplotypes 
(HLAs-A2, -DR4, -DR7, and –DQB1*0303) and other 
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genes (Tab. 1) which are implicated in both cellular 
and humoral immunity [4][5][6). Because the possible 
associated to different autoimmune diseases, in 
future, the recognition of the genetic background 
should be helpful to recognize eventual comorbidities 
and personalized focused treatment. 
Table 1: some of gene which may be alterated in vitiligo 
patients 
Gene  Protein  Function  Comorbilities  
RERE  Atrophin like protein 1  Regulation apoptosis   
PTPN22  Lymphoid specific protein 
tyrosinase phosphatase 
nonreceptor 22  
Regulation T cell 
receptor signaling  
Type 1 DM, Grave’s 
disease, RA, Addison’s 
disease, psoriasis, IBD  
CTLA4B  Cytotoxic T lymphocytes 
antigen 4  
Inhibition of T cells  Type 1 DM, Grave’s 
disease, Hashimoto’s 
thyroiditis, IBD, SLE 
FOXP1  Forkhead box P1  Regulation of 
lymphoid cell 
development  
 
TSLP  Thymic stromal 
lymphoprotein  
Regulation of T cell 
and DC maturation  
 
CCR6  Chemokine receptor type 6 Regulation of B cell 
differentiation  
IBD, AR, Grave’s disease 
IL2RA  Interleukin 2 receptor  Regulation of 
lymphocyte response 
to bacteria  
Type 1 DM, Grave’s 
disease, RA,  multiple 
sclerosis, SLE  
GZMB  Granzyme B  Mediator of T cell and 
NK apoptosis  
 
FOXP3  Forkhead box P3  Regulation of T-reg   
 
 
Environmental factors 
 
Many data support the deep impact of 
environmental factors in the development of vitiligo. 
First at all, there is the evidence of a variable 
prevalence of the disease in different countries, which 
range from 0.1 to 2.0%. 
Then there are the data about the incidence 
of the disease among familiarities. It has been 
estimated that most of the cases of vitiligo are 
sporadic and up to 20% of patients report an affected 
relative. Moreover, the incidence of concordance of 
vitiligo in monozygotic twins is only 23% [7]. 
Different environmental factors (Tab. 2) may 
trigger the disease: their recognition would be 
fundamental to limit the incidence and progression of 
the skin disease. 
Table 2: Trigger factors which may be involved in vitiligo onset 
Physical stress: major illness, surgical operations, accidents  
Intercurrent infections and repeated antibiotic- intake 
UVR and sunburns  
Chemical factors: Thiols, Phenols, Catechols, Mercaptoamines, Quinones and their 
derivatives 
Endocrine factors: pregnancy 
Malnutrition: malnutritional habits, intake of preserved, stale, junk flood 
Psycho-social insecurity/shocks  
 
 
Pathobiology 
 
Today the exact pathobiology of vitiligo is 
still unclear. Even if multiple theories have been 
proposed (Tab. 3), recent data support that vitiligo is a 
T-cell mediated autoimmune disease, triggered by 
oxidative stress [8]. In melanocytes, the progressive 
accumulation of reactive oxygen species (ROS) 
causes DNA damage, lipid and protein peroxidation. 
Many are the proteins altered, showing partial or 
complete loss of their functionality. In particular 
tyrosinase is found to be inhibited by the high 
concentrations of hydrogen peroxide [9]. Also 
keratinocytes are significantly altered by oxidative 
stress, leading to a deficit of their trophic support to 
melanocytes [10]. 
Table 3: Pathobiological theories for vitiligo 
• Oxydative stress theory 
• Autoimmune theory 
• Neurohumoral theory 
• Autocytotoxic theory 
• Biochemical theory 
• Melanocytorrhagy theory 
• Theory of decreased melanocyte lifespan 
• Inflammatory theory 
 
 
Clinic of vitiligo 
 
Classically, vitiligo is characterized by 
asymptomatic white macules, varying in form and 
size. Although it is more often localized on body 
folds, periorificial and sun-exposed areas, vitiligo may 
affect different part of the body, both cutaneous and 
mucosal. Occasionally, patients may show the 
damage of the hair follicles’ melanocytes, which result 
in depigmentated hairs (also known as “leukotrichia”). 
Characteristic is the Koebner’s phenomenon, 
consisting in the development of new lesions at sites 
of skin trauma. 
Table 4: Clinical variant of vitiligo [11-12] 
Type of vitiligo Characteristics  
Punctata vitiligo little, punctuate-like, depigmented macules 
Follicular vitiligo vitiligo involving the follicular reservoir with poor cutaneous 
lesions 
Inflammatory vitiligo erythematous halo surrounding the white patches 
Trichrome vitiligo hypo-pigmented area between the central amelanotic zone and 
the peripheral normal skin 
Quadrichrome vitiligo variant of trichrome vitiligo with foci of repigmentation at the 
follicular osti 
Pentachrome vitiligo lesions show the occurrence of five shade of color, by white to 
black 
Blue vitiligo bluish appearance of skin color 
 
In addition to such more common clinical 
features, vitiligo patients may also show abnormalities 
of the melanocytes localized in different districts (e.g. 
eyes, ears, brain, heart and lungs) [13]. 
 
 
Classification 
 
Another classification of the skin disease, 
often preferred to the first one, is based on the clinical 
feature and natural history of vitiligo (Tab. 6) [14]. 
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Table 5: classification of vitiligo on the basis of the disease 
distribution 
 
 
Recognize the type of vitiligo has important 
implication for the management of the patient, 
because for each form there is a different prognosis 
(Tab. 7). 
Table 6: Classification of vitiligo based on the clinical feature 
and natural history of the disease 
Types  Characteristics  Subtypes  
Segmental vitiligo (SV) One or more vitiliginous 
patches, in a linear or flag-like 
pattern of mosaicism, with a 
unilateral dermatomal 
distribution 
Unisegmental 
Bisegmental 
Multisegmental  
Non-segmental vitligo (NSV) Heterogeneous group of 
pigmentary disorders with 
different localization, usually in 
a symmetric pattern 
Acrofacial 
Mucosal (more than 1 side 
affected) 
Generalized 
Universal 
Mixed (associated with 
segmental vitiligo) 
Rare forms 
Unclassified or 
indeterminate 
 Focal 
Mucosal (only one side) 
 
 
Comorbidities 
 
The increased risk of developing autoimmune 
diseases of vitiligo patients is a well-known data (Tab. 
8) [15].  
Table 7: Prognosis of different forms of vitiligo 
 Localized – stable, regressive  
 Generalized – progressive, systemic, possible association with other 
autoimmune diseases 
 Universalis – common association with comorbidities  
 
Even if at the moment no laboratory 
biomarker are available to evaluate the possible 
association with autoimmune comorbidities, it is 
recommended to rule out the presence of associated 
diseases thought the commonest autoimmune 
antibodies and clinical laboratory data (Tab. 9). 
Table 8: common autoimmune diseases associated to vitligo 
 Alopecia areata 
 Atopic dermatitis 
 Autoimmune hemolytic anemia 
 Autoimmune thyroid disease 
 Diabetes mellitus 
 Inflammatory bowel disease 
 Morphea 
 Multiple sclerosis 
 Pemphigus vulgaris 
 Pernicious anemia 
 Psoriasis 
 Rheumatoid arthritis 
 Systemic lupus erythematosus 
 Others  
Finally, even if more rare especially in 
childhood, recent studies underline the possible 
association of vitiligo with different diseases, such as 
endocrinologic ones (e.g. hypoparathyroidism) and 
systemic inflammatory disorders (e.g. obesity, 
metabolic syndrome) [16]. 
Table 9: Antibodies and laboratory data to be checked in a 
patient with vitiligo 
Ab to be checked  
 Routine  
o Anti-thyroid peroxidase Ab (ATPO) 
o Anti-thyroglobulin Ab (ATG) 
o Anti-thyroid 
o Anti-parietal gastric cell antibody 
o Total IgE  
 Second line  
o Anti-nuclear Ab (ANA) 
o Additional autoantibodies (only if patient’s history, family history 
and ⁄ or laboratory parameters highlight a strong risk of 
additional autoimmune disease or if endocrinologist 
⁄immunologist advice if multiple autoimmune syndrome 
detected 
Laboratory data 
 Thyroid stimulating hormone (TSH) 
 Eosinophil count 
 Vitamin B12 
 Folic acid 
 
 In conclusion, vitiligo may be considered as a 
spectrum of diseases with different clinical 
presentations, unknown etiology, fragmented genetic 
data and pathobiological hypothesis. We strongly 
affirm the importance of a better knowledge of the 
etio-pathobiology and clinic of the disease, for a 
better management of the patients. 
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